Preclinical in vivo validation of the RAD51 test for identification of homologous recombination-deficient tumors and patient stratification

PARP inhibitors (PARPi) are approved drugs for platinum-sensitive, high-grade serous ovarian cancer (HGSOC) and for breast (BC), prostate, and pancreatic cancers (PaC) harboring genetic alterations impairing homologous recombination repair (HRR). Detection of nuclear RAD51 foci in tumor cells is a m...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Res
Hauptverfasser: Pellegrino, Benedetta, Herencia-Ropero, Andrea, Llop-Guevara, Alba, Pedretti, Flaminia, Moles-Fernández, Alejandro, Viaplana, Cristina, Villacampa, Guillermo, Guzmán, Marta, Rodríguez, Olga, Grueso, Judit, Jiménez, Jose, Arenas, Enrique J., Degasperi, Andrea, Dias, João M. L., Forment, Josep V., O’Connor, Mark J., Déas, Olivier, Cairo, Stefano, Zhou, Yinghui, Musolino, Antonino, Caldas, Carlos, Nik-Zainal, Serena, Clarke, Robert B., Nuciforo, Paolo, Díez, Orland, Serres-Créixams, Xavier, Peg, Vicente, Espinosa-Bravo, Martín, Macarulla, Teresa, Oaknin, Ana, Mateo, Joaquin, Arribas, Joaquín, Dienstmann, Rodrigo, Bellet, Meritxell, Oliveira, Mafalda, Saura, Cristina, Gutiérrez-Enríquez, Sara, Balmaña, Judith, Serra, Violeta
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2022
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7612637/
https://ncbi.nlm.nih.gov/pubmed/35425960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-21-2409
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge